In Part One of this two-part series, we reflected on the progress made in the Cell and Gene Therapy (CGT) industry and the importance of patient-centric development. In this episode, we dive into how we can continue to move forward, broaden access, and encourage the development of new treatments. We’ll discuss the critical need to scale manufacturing, even in the early stages of development, to ensure that these therapies reach the patients who need them. Guests:<ul><li><a href="https://www.linkedin.com/in/emma-chan-3680278b/?originalSubdomain=uk" target="_blank" style="background-color: transparent;">Emma Chan</a>, Director of Technical Development at Orchard Therapeutics</li><li><a href="https://www.linkedin.com/in/matthewmhewitt/" target="_blank" style="background-color: transparent;">Matt Hewitt</a>, Chief Technical Officer at the Manufacturing Business Division at Charles River Laboratories</li></ul>

<description>&lt;p&gt;&lt;span style="background-color: transparent;"&gt;In Part One of this two-part series, we reflected on the progress made in the Cell and Gene Therapy (CGT) industry and the importance of patient-centric development. In this episode, we dive into how we can continue to move forward, broaden access, and encourage the development of new treatments. We’ll discuss the critical need to scale manufacturing, even in the early stages of development, to ensure that these therapies reach the patients who need them.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;strong style="background-color: transparent;"&gt;Guests:&lt;/strong&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;a href="https://www.linkedin.com/in/emma-chan-3680278b/?originalSubdomain=uk" target="_blank" style="background-color: transparent;"&gt;Emma Chan&lt;/a&gt;&lt;span style="background-color: transparent;"&gt;, Director of Technical Development at Orchard Therapeutics&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="https://www.linkedin.com/in/matthewmhewitt/" target="_blank" style="background-color: transparent;"&gt;Matt Hewitt&lt;/a&gt;&lt;span style="background-color: transparent;"&gt;, Chief Technical Officer at the Manufacturing Business Division at Charles River Laboratories&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;</description>

In Part One of this two-part series, we reflected on the progress made in the Cell and Gene Therapy (CGT) industry and the importance of patient-centric development. In this episode, we dive into how we can continue to move forward, broaden access,...

Part Two: How Innovation Can Broaden Access and Propel the CGT Industry Forward

The Cell and Gene Therapy (CGT) industry has made remarkable strides, with significant advancements and the approval of groundbreaking technologies in recent years. However, have we become too dependent on older methods, and are we doing enough to ensure these new therapies are reaching as many patients as possible? In this episode, we tackle these questions while exploring one fundamental issue: Why? Why is it essential to continue innovating to broaden patient access, develop new therapies, and push the industry forward? Guests: <ul><li>Tay Salimullah, Chief Access Commercial Officer at Novartis</li><li>Jason Jones, Global Business Development Lead at Cellular Origins</li></ul>

<description>&lt;p&gt;&lt;span style="background-color: transparent;"&gt;The Cell and Gene Therapy (CGT) industry has made remarkable strides, with significant advancements and the approval of groundbreaking technologies in recent years. However, have we become too dependent on older methods, and are we doing enough to ensure these new therapies are reaching as many patients as possible? In this episode, we tackle these questions while exploring one fundamental issue: Why? Why is it essential to continue innovating to broaden patient access, develop new therapies, and push the industry forward?&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;strong style="background-color: transparent;"&gt;Guests:&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;span style="background-color: transparent;"&gt;Tay Salimullah, Chief Access Commercial Officer at Novartis&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span style="background-color: transparent;"&gt;Jason Jones, Global Business Development Lead at Cellular Origins&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;</description>

The Cell and Gene Therapy (CGT) industry has made remarkable strides, with significant advancements and the approval of groundbreaking technologies in recent years. However, have we become too dependent on older methods, and are we doing enough to ...

Part One: Why Do We Need to Continue Innovating in the CGT Industry?

Welcome back to Invent: Life Sciences, a podcast brought to you by technology and product development company TTP. With approvals for advanced therapies on the rise, and aspirations to target larger patient populations, it’s time to take stock and reflect and on the progress made to date. In this series, we’ll be looking at the people, processes and partnerships we’ll need to continue moving forwards and delivering the best outcomes for the greatest number of patients. Over the forthcoming two episodes, I’ll be joined by 4 expert guests to answer two fundamental questions: why do we need to continue to innovate, and how can we do it.

<description>&lt;p&gt;&lt;span style="background-color: transparent;"&gt;Welcome back to Invent: Life Sciences, a podcast brought to you by technology and product development company TTP. &lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;span style="background-color: transparent;"&gt;With approvals for advanced therapies on the rise, and aspirations to target larger patient populations, it’s time to take stock and reflect and on the progress made to date. In this series, we’ll be looking at the people, processes and partnerships we’ll need to continue moving forwards and delivering the best outcomes for the greatest number of patients.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;span style="background-color: transparent;"&gt;Over the forthcoming two episodes, I’ll be joined by 4 expert guests to answer two fundamental questions: &lt;/span&gt;&lt;strong style="background-color: transparent;"&gt;why&lt;/strong&gt;&lt;span style="background-color: transparent;"&gt; do we need to continue to innovate, and &lt;/span&gt;&lt;strong style="background-color: transparent;"&gt;how&lt;/strong&gt;&lt;span style="background-color: transparent;"&gt; can we do it.&lt;/span&gt;&lt;/p&gt;</description>

Welcome back to Invent: Life Sciences, a podcast brought to you by technology and product development company TTP. With approvals for advanced therapies on the rise, and aspirations to target larger patient populations, it’s time to take stock and ...

Welcome Back to Invent: Life Sciences - Season 3 Trailer

Throughout this series of Invent, we have brought you cutting-edge developments in the Life Sciences industry. We have spoken to a wide range of guests who have provided fascinating insights into the manufacture of cell and gene therapies, and what developments in drug testing mean for the future of genetic research. A big thank you to all our guests that featured in this series, make sure you show your appreciation to our esteemed guests by re-listening to your favorite episode and subscribing to Invent: Life Sciences from wherever you get your podcasts. And finally, a big thank you to you, our listeners, for tuning in each week throughout this series. What has been your favorite episode? Get in touch and let us know! So for the last time in this series... join me, Stuart Lowe, as we dive into the best bits of Invent: Life Sciences Series 2, a podcast brought to you by technology and product development company TTP.

<description>
 &lt;p&gt;Throughout this series of Invent, we have brought you cutting-edge developments in the Life Sciences industry. &lt;/p&gt;&lt;p&gt;We have spoken to a wide range of guests who have provided fascinating insights into the manufacture of cell and gene therapies, and what developments in drug testing mean for the future of genetic research. &lt;/p&gt;&lt;p&gt;A big thank you to all our guests that featured in this series, make sure you show your appreciation to our esteemed guests by re-listening to your favorite episode and subscribing to Invent: Life Sciences from wherever you get your podcasts. &lt;/p&gt;&lt;p&gt;And finally, a big thank you to you, our listeners, for tuning in each week throughout this series. What has been your favorite episode? Get in touch and let us know!&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;So for the last time in this series... join me, Stuart Lowe, as we dive into the best bits of Invent: Life Sciences Series 2, a podcast brought to you by technology and product development company TTP.&lt;/p&gt;
 </description>

Throughout this series of Invent, we have brought you cutting-edge developments in the Life Sciences industry. We have spoken to a wide range of guests who have provided fascinating insights into the manufacture of cell and gene therapies, and what...

The Highlights: A look back at the best moments of Invent: Life Sciences Series 2

Throughout this series, we’ve explored different diseases we target, the sorts of cells which are under development as therapies, and how the therapies themselves are manufactured. With all this innovation, we shouldn’t be surprised by the increased focus on the means by which processes and products themselves are characterised. So, do current process analytical tools provide the insights therapy developers need? And how can new technologies be implemented in the fast-moving life sciences field? To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP. This Week's Guests Davide Danovi Davide Danovi leads the cellular pheotyping department at bit.bio. Bit.bio is an award-winning human synthetic biology enterprise with a mission to code cells for health through applying the principles of computation to biology. In his role at bit.bio, Davide's responsibilities emcompass three key areas. Firstly, Infrastructure and training, overseeing the maintenance of essential instruments, conducts staff training, and establishes data analysis infrastructure for imaging and flow cytometry. Secondly, Cell characterisation, verifying the identities of cells, ensuring the accuracy and reliability of experimental results. And finally, Cell type identification, developing modules to precisely identify specific cell types by screening transcription factors, offering innovative solutions for cell identification.James Kusena James Kusena is the Vice President of Operations at MicrofluidX. MicrofluidX is industrialising cell and gene therapy manufacturing through it's latest technology, the Cyto Engine, a unified bioreactor and data platform for cell and gene therapy research, development, and manufacturing. James' career began with a focus on bioprocessing and applications, now as VP of Operations, this focus is now shaping the company's technology to align with industry needs. With demonstrated experience in various sectors of the Cell and Gene therapy industry, including: Process Development, Process Translation, Process Transfer, Research &amp; Development and Commercialisation; James' career reflects a fusion of technical expertise and leadership with a commitment to advancing cell therapy manufacturing industry standards and product quality.

<description>
 &lt;p&gt;Throughout this series, we’ve explored different diseases we target, the sorts of cells which are under development as therapies, and how the therapies themselves are manufactured. With all this innovation, we shouldn’t be surprised by the increased focus on the means by which processes and products themselves are characterised. So, do current process analytical tools provide the insights therapy developers need? And how can new technologies be implemented in the fast-moving life sciences field?&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;strong&gt;This Week's Guests&lt;br&gt;&lt;/strong&gt;&lt;br&gt;&lt;strong&gt;Davide Danovi&lt;/strong&gt;&lt;br&gt;Davide Danovi leads the cellular pheotyping department at bit.bio. Bit.bio is an award-winning human synthetic biology enterprise with a mission to code cells for health through applying the principles of computation to biology. In his role at bit.bio, Davide's responsibilities emcompass three key areas. Firstly, Infrastructure and training, overseeing the maintenance of essential instruments, conducts staff training, and establishes data analysis infrastructure for imaging and flow cytometry. Secondly, Cell characterisation, verifying the identities of cells, ensuring the accuracy and reliability of experimental results. And finally, Cell type identification, developing modules to precisely identify specific cell types by screening transcription factors, offering innovative solutions for cell identification.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;James Kusena&lt;/strong&gt;&lt;br&gt;James Kusena is the Vice President of Operations at MicrofluidX. MicrofluidX is industrialising cell and gene therapy manufacturing through it's latest technology, the Cyto Engine, a unified bioreactor and data platform for cell and gene therapy research, development, and manufacturing. James' career began with a focus on bioprocessing and applications, now as VP of Operations, this focus is now shaping the company's technology to align with industry needs. With demonstrated experience in various sectors of the Cell and Gene therapy industry, including: Process Development, Process Translation, Process Transfer, Research &amp;amp; Development and Commercialisation; James' career reflects a fusion of technical expertise and leadership with a commitment to advancing cell therapy manufacturing industry standards and product quality.&lt;/p&gt;
 </description>

Throughout this series, we’ve explored different diseases we target, the sorts of cells which are under development as therapies, and how the therapies themselves are manufactured. With all this innovation, we shouldn’t be surprised by the increase...

Process Analytics: how can analytics accelerate the development and manufacture of cell and gene therapies?

What are the biggest challenges and opportunities facing the life sciences sector? How can we overcome these challenges while unlocking the opportunities? Join host Stuart Lowe and a roster of expert guests as they unpack the past, present and future of cell and gene therapy. 


Invent: Life Sciences

Details

Recent Episodes